TY - JOUR
T1 - Zika Vaccine Development
T2 - Current Status
AU - Poland, Gregory A.
AU - Ovsyannikova, Inna G.
AU - Kennedy, Richard B.
N1 - Funding Information:
Potential Competing Interests: Dr Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories and is a consultant on vaccine development to Merck & Co. Inc, Avianax LLC, Adjuvance, Valneva SE, Medicago Inc, Sanofi Pasteur Limited, GlaxoSmithKline plc, and Emergent BioSolutions Inc. Drs Poland and Ovsyannikova hold 3 patents related to vaccinia and measles peptide vaccines. Dr Kennedy holds a patent related to vaccinia peptide vaccines and has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Publisher Copyright:
© 2019 Mayo Foundation for Medical Education and Research
PY - 2019/12
Y1 - 2019/12
N2 - Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effects—as well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical results, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection. Whether such vaccines can be developed through to licensure and public availability absent significant financial investment by countries, and other barriers discussed within this article, remains uncertain.
AB - Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effects—as well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical results, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection. Whether such vaccines can be developed through to licensure and public availability absent significant financial investment by countries, and other barriers discussed within this article, remains uncertain.
UR - http://www.scopus.com/inward/record.url?scp=85071855390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071855390&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2019.05.016
DO - 10.1016/j.mayocp.2019.05.016
M3 - Review article
C2 - 31806107
AN - SCOPUS:85071855390
SN - 0025-6196
VL - 94
SP - 2572
EP - 2586
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 12
ER -